Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031055 · ClinicalTrials.gov registry record · Phase 1
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02031055 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Taiho Oncology. The registered enrollment target is 8 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02031055, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate, in patients with advanced solid tumors, the mass balance of FTD and TPI after a single dose of TAS-102 with a light tracer dose of \[14C\]FTD or \[14C\]TPI.
Conditions Studied
Interventions
- DRUG TAS-102 with a light tracer dose of [14C]FTD
- DRUG TAS-102 with a light tracer dose of [14C] TPI
- DRUG TAS-102 tablets
Study Locations (1)
Pennsylvania
- University of Pittsbutgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02031055
The ClinicalTrials.gov registry entry for NCT02031055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (96% lower). The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which TAS-102 with a light tracer dose of [14C]FTD is the first listed.
NCT02031055 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02031055 about?
NCT02031055 is a clinical study titled "Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors". The purpose of this study is to evaluate, in patients with advanced solid tumors, the mass balance of FTD and TPI after a single dose of TAS-102 with a light tracer dose of \[14C\]FTD or \[14C\]TPI.
What is the current status of trial NCT02031055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-02. Estimated completion is 2015-06-17.
What conditions does trial NCT02031055 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02031055?
The interventions under investigation include: TAS-102 with a light tracer dose of [14C]FTD (DRUG), TAS-102 with a light tracer dose of [14C] TPI (DRUG), TAS-102 tablets (DRUG).
Who is sponsoring clinical trial NCT02031055?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02031055 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.